Atrium Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	35.84	18.62	10.9	9.76
Revenue Growth	-	70.85%	11.60%	-
Cost of Revenue	56.04	44.27	19.2	12.65
Gross Profit	-20.2	-25.65	-8.3	-2.89
Selling, General & Admin	49.01	23.98	4.92	3.5
Operating Expenses	49.01	23.98	4.92	3.5
Operating Income	-69.21	-49.63	-13.22	-6.39
Other Non Operating Income (Expenses)	0.32	-0.01	0	0
Pretax Income	-66.13	-49.64	-13.22	-6.39
Income Tax Expense	-0.14	-0.14	11.91	-
Net Income	-65.99	-49.5	-25.12	-6.39
Net Income to Common	-65.99	-49.5	-25.12	-6.39
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	17	16	-	-
Shares Outstanding (Diluted)	17	16	-	-
Shares Change	-	-	-	-
EPS (Basic)	-3.86	-3.19	-	-
EPS (Diluted)	-3.86	-3.19	-	-
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Free Cash Flow	-56.5	-42.57	-22.82	56.07
Free Cash Flow Per Share	-3.30	-2.74	-	-
Gross Margin	-56.37%	-137.76%	-76.19%	-29.59%
Operating Margin	-193.13%	-266.57%	-121.30%	-65.40%
Profit Margin	-184.15%	-265.88%	-230.54%	-65.39%
Free Cash Flow Margin	-157.66%	-228.67%	-209.41%	574.25%
EBITDA	-68.53	-49.31	-13.05	-6.25
EBITDA Margin	-191.22%	-264.84%	-119.72%	-63.99%
D&A For EBITDA	0.69	0.32	0.17	0.14
EBIT	-69.21	-49.63	-13.22	-6.39
EBIT Margin	-193.13%	-266.57%	-121.30%	-65.40%